The absolute risk reduction in fatal and nonfatal CHD with pravastatin treatment was 1.6 % ( 95 % CI = -1.6 to 4.7 % ) in the low homocysteine group and 6.7 % ( 95 % CI = 2.7-10 .7 % ) in the high homocysteine group ( difference 5.2 % , 95 % CI = 0.11-10 .3 , P = .046 ) .